NASDAQ:GRCL

Gracell Biotechnologies - GRCL Stock Forecast, Price & News

$3.37

-0.11 (-3.16%)

(As of 11/25/2022 08:57 PM ET)

Add

Compare

Today's Range: $3.37
▼
$3.37
50-Day Range: $2.08
▼
$3.96
52-Week Range: $1.68
▼
$7.96

Volume: 1,600 shs
Average Volume: 154,599 shs
Market Capitalization: $228.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Gracell Biotechnologies MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 345.1% Upside
$15.00 Price Target
Short Interest: Bearish
0.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.04
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.29) to ($0.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

693rd out of 1,044 stocks

Pharmaceutical Preparations Industry

326th out of 510 stocks

3.5

Analyst's Opinion

Consensus Rating
Gracell Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Gracell Biotechnologies has a forecasted upside of 345.1% from its current price of $3.37.
Amount of Analyst Coverage
Gracell Biotechnologies has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.58% of the float of Gracell Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
Gracell Biotechnologies has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in Gracell Biotechnologies has recently increased by 31.13%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Gracell Biotechnologies does not currently pay a dividend.
Dividend Growth
Gracell Biotechnologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRCL.

2.2

News and Social Media Coverage

News Sentiment
Gracell Biotechnologies has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Gracell Biotechnologies this week, compared to 1 article on an average week.
Search Interest
5 people have searched for GRCL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
1 people have added Gracell Biotechnologies to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gracell Biotechnologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.00% of the stock of Gracell Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.29% of the stock of Gracell Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Gracell Biotechnologies are expected to decrease in the coming year, from ($0.29) to ($0.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gracell Biotechnologies is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gracell Biotechnologies is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gracell Biotechnologies has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gracell Biotechnologies (NASDAQ:GRCL) Stock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

GRCL Stock News Headlines

November 19, 2022 | americanbankingnews.com

FY2026 EPS Estimates for Gracell Biotechnologies Inc. Lifted by Analyst (NASDAQ:GRCL)

November 14, 2022 | seekingalpha.com

Gracell Biotechnologies Inc. (GRCL) Q3 2022 Results - Earnings Call Transcript

November 14, 2022 | finanznachrichten.de

Gracell Biotechnologies Inc.: Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

November 14, 2022 | finance.yahoo.com

Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

November 3, 2022 | finance.yahoo.com

Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition

October 31, 2022 | finance.yahoo.com

Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

October 24, 2022 | finance.yahoo.com

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

October 17, 2022 | finance.yahoo.com

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

August 16, 2022 | investing.com

Gracell Biotechnologies Inc. Misses Q2 EPS by 15c

August 15, 2022 | seekingalpha.com

Gracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q2 2022 Results - Earnings Call Transcript

August 15, 2022 | finance.yahoo.com

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

August 8, 2022 | finance.yahoo.com

Do Institutions Own Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares?

August 2, 2022 | seekingalpha.com

Gracell Biotechnologies rallies after naming new chief medical officer

August 2, 2022 | finance.yahoo.com

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

August 1, 2022 | finance.yahoo.com

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

July 19, 2022 | finance.yahoo.com

Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

June 21, 2022 | seekingalpha.com

Gracell Biotechnologies (GRCL) Presents at the 27th Congress of the European Hematology Association (EHA) - Slideshow

June 13, 2022 | marketwatch.com

Gracell Biotechnologies Shares Reverse Course, Drop 13% After Study Results

June 13, 2022 | finance.yahoo.com

Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients

June 12, 2022 | finance.yahoo.com

Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients

June 3, 2022 | finance.yahoo.com

Gracell Biotechnologies Schedules Clinical Update Call After EHA2022

May 26, 2022 | finance.yahoo.com

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting

May 19, 2022 | finance.yahoo.com

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

May 17, 2022 | seekingalpha.com

Gracell Biotechnologies GAAP EPS of -$0.07 in-line

May 16, 2022 | seekingalpha.com

Gracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q1 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

GRCL Company Calendar

Last Earnings: 11/14/2022
Today: 11/27/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/13/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GRCL
CUSIP: N/A
CIK: 1826492
Web: www.gracellbio.com
Phone: 86-512-6262-6701
Fax: N/A
Employees: 348
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +345.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,890,000.00
Net Margins: N/A
Pretax Margin: -154,287.73%
Return on Equity: -36.26%
Return on Assets: -31.17%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 6.77
Quick Ratio: 6.77

Sales & Book Value

Annual Sales: $60,000.00
Price / Sales: 3,801.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.17 per share
Price / Book: 1.06

Miscellaneous

Outstanding Shares: 67,674,000
Free Float: 48,725,000
Market Cap: $228.06 million
Optionable: Not Optionable
Beta: -2.46

Key Executives

Dr. Wei Cao (Age 63)
Founder, Chairman & CEO

Dr. Yili Xie M.B.A. (Age 51)
Ph.D., Chief Financial Officer

Dr. Yajin Ni M.D. (Age 59)
Ph.D., Chief Technology Officer

Dr. Samuel Suhua Zhang M.B.A.
Ph.D., Chief Bus. Officer

Dr. Wendy Li M.D.
Chief Medical Officer

Ms. Erin Li
Exec. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GRCL Stock - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRCL shares.
View GRCL analyst ratings or view top-rated stocks.
What is Gracell Biotechnologies' stock price forecast for 2023?: 4 Wall Street research analysts have issued 1-year price targets for Gracell Biotechnologies' stock. Their GRCL share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 345.1% from the stock's current price.
View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts.
How have GRCL shares performed in 2022?: Gracell Biotechnologies' stock was trading at $6.04 at the beginning of the year. Since then, GRCL stock has decreased by 44.2% and is now trading at $3.37.
View the best growth stocks for 2022 here.
When is Gracell Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our GRCL earnings forecast.
How were Gracell Biotechnologies' earnings last quarter?: Gracell Biotechnologies Inc. (NASDAQ:GRCL) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.27.
When did Gracell Biotechnologies IPO?: (GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO.

What is Gracell Biotechnologies' stock symbol?: Gracell Biotechnologies trades on the NASDAQ under the ticker symbol "GRCL."
Who are Gracell Biotechnologies' major shareholders?: Gracell Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.41%), Balyasny Asset Management LLC (0.04%) and Tower Research Capital LLC TRC (0.01%).
How do I buy shares of Gracell Biotechnologies?: Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gracell Biotechnologies' stock price today?: One share of GRCL stock can currently be purchased for approximately $3.37.
How much money does Gracell Biotechnologies make?: Gracell Biotechnologies (NASDAQ:GRCL) has a market capitalization of $228.05 million and generates $60,000.00 in revenue each year. The company earns $-70,890,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.
How many employees does Gracell Biotechnologies have?: The company employs 348 workers across the globe.
How can I contact Gracell Biotechnologies?: The official website for the company is www.gracellbio.com. The company can be reached via phone at 86-512-6262-6701 or via email at ir@gracellbio.com.

This page (NASDAQ:GRCL) was last updated on 11/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial